Invention Application
- Patent Title: BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
-
Application No.: US17559938Application Date: 2021-12-22
-
Publication No.: US20220144964A1Publication Date: 2022-05-12
- Inventor: Brian ELLIOTT , Tahamtan AHMADI , Christopher W. L. CHIU , Esther C. W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
- Applicant: GENMAB A/S
- Applicant Address: DK Copenhagen V
- Assignee: GENMAB A/S
- Current Assignee: GENMAB A/S
- Current Assignee Address: DK Copenhagen V
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K31/454
Abstract:
Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
Public/Granted literature
- US11608383B2 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma Public/Granted day:2023-03-21
Information query
